Patents by Inventor Tina Moller Tagmose

Tina Moller Tagmose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Acylated Single Chain Insulin
    Publication number: 20090099065
    Abstract: The invention is related to an acylated, single-chain insulin comprising the B- and the A-chain of human insulin or an analogue thereof connected by a connecting peptide, wherein a lysine residue being substituted for the natural amino acid residue in one of the positions A12-A23 in the human insulin A-chain has been chemically modified by acylation.
    Type: Application
    Filed: March 12, 2007
    Publication date: April 16, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Borglum Kjeldsen, Tina Moller Tagmose
  • Acylated Single Chain Insulin
    Publication number: 20090069215
    Abstract: The invention is related to an acylated, single-chain insulin comprising the B- and the A-chain of human insulin or an analogue thereof connected by a connecting peptide, wherein a lysine residue being substituted for the natural amino acid residue in at least one of the positions B20, B21 or B22 in the human insulin B-chain is chemically modified by acylation.
    Type: Application
    Filed: March 12, 2007
    Publication date: March 12, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Borglum Kjeldsen, Tina Moller Tagmose
  • Tetrahydronaphtalene derivatives and their use
    Patent number: 6410743
    Abstract: Tetrahydronaphatalene derivatives, and compositions comprising the compounds. The tetrahydronaphatalene derivates are useful in inhibiting a rise in intracellular calcium mediated by an influx through T-type calcium channels, and are thus useful for treatment of, for example, type 1 and type 2 diabetes and cardiovascular diseases associated with diabetes.
    Type: Grant
    Filed: March 27, 2001
    Date of Patent: June 25, 2002
    Assignees: Novo Nordisk A/S, South Alabama Medical Science Foundation
    Inventors: Ming Li, John Bondo Hansen, Tina Moller Tagmose
  • Substituted 3,3-diamino-2-propenenitriles, their preparation and use
    Patent number: 6365609
    Abstract: Described are substituted cyanoenamines of formula I wherein Z, R1, R2 and R3 are defined in the description, compositions thereof and methods for preparing these compounds. These compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinologic system.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: April 2, 2002
    Assignee: Novo Nordisk A/S
    Inventors: John Bondo Hansen, Tina Moller Tagmose, John Patrick Mogensen, Florencio Zaragoza Dorwald, Anker Steen Jorgensen
  • Substituted 3,3-diamino-2-propenenitriles, their preparation and use
    Patent number: 6362205
    Abstract: Described are substituted cyanoenamines of formula I wherein Z, R1, R2 and R3 are defined in the description, compositions thereof and methods for preparing these compounds. These compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinologic system.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: March 26, 2002
    Assignee: Novo Nordisk A/S
    Inventors: John Bondo Hansen, Tina Moller Tagmose, John Patrick Mogensen, Florencio Zaragoza Dorwald, Anker Steen Jorgensen
  • Substituted 3,3-diamino-2-propenenitriles, their preparation and use
    Publication number: 20010056188
    Abstract: Disclosed are substituted cyanoenamines, compositions containing these compounds, and methods for preparing these compounds. These compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinologic system.
    Type: Application
    Filed: March 16, 2001
    Publication date: December 27, 2001
    Inventors: John Bondo Hansen, Tina Moller Tagmose, John Patrick Mogensen, Florencio Zaragoza Dorwald, Anker Steen Jorgensen
  • Mibefradil analogues and their use
    Publication number: 20010049447
    Abstract: The present invention relates to mibefradil analogues, to compositions comprising the compounds and their use in therapy, e.g. in the treatment and/or prevention of type 1 and type 2 diabetes as well as microvascular or macrovascular diseases associated with diabetes.
    Type: Application
    Filed: March 27, 2001
    Publication date: December 6, 2001
    Inventors: Ming Li, John Bondo Hansen, Tina Moller Tagmose
  • Tetrahydronaphtalene derivatives and their use
    Publication number: 20010041730
    Abstract: Tetrahydronaphatalene derivatives, and compositions comprising the compounds. The tetrahydronaphatalene derivates are useful in inhibiting a rise in intracellular calcium mediated by an influx through T-type calcium channels, and are thus useful for treatment of, for example, type 1 and type 2 diabetes and cardiovascular diseases associated with diabetes.
    Type: Application
    Filed: March 27, 2001
    Publication date: November 15, 2001
    Inventors: Ming Li, John Bondo Hansen, Tina Moller Tagmose
  • Substituted 3,3-diamino-2-propenenitriles, their preparation and use
    Publication number: 20010025111
    Abstract: Substituted cyanoenamines of the general formula I 1
    Type: Application
    Filed: May 3, 2001
    Publication date: September 27, 2001
    Inventors: John Bondo Hansen, Tina Moller Tagmose, John Patrick Mogensen, Florencio Zaragoza Dorwald, Anker Steen Jorgensen
  • 1,2,4-benzothiadiazine derivatives, their preparation and use
    Patent number: 6242443
    Abstract: 1,2,4-Benzothiadiazine derivatives represented by formula wherein D, R1, R2, R3, R4, R5, R12, R13, R14, R15 are defined in the description, composition thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.
    Type: Grant
    Filed: June 17, 1997
    Date of Patent: June 5, 2001
    Assignee: Novo Nordisk AIS
    Inventors: Bernard Pirotte, Philippe Lebrun, Pascal De Tullio, Fabian Somers, Jacques Delarge, John Bondo Hansen, Flemming Elmelund Nielsen, Holger Claus Hansen, John Patrick Mogensen, Tina Møller-Tagmose
  • Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use
    Patent number: 6232310
    Abstract: The present invention relates to fused 1,4-thiazine-2-carbonitrile derivatives, compositions thereof and methods for preparing the compounds. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: May 15, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Holger Claus Hansen, Tina Møller Tagmose, John Bondo Hansen
  • Fused 1,2,4-thiadiazine derivatives, their preparation and use
    Patent number: 6225310
    Abstract: 1,2,4-Thiadiazine and 1,4-thiazine derivates represented by formula (I): wherein A, B, D, R1, R2, R3 and R4 are defined in the description, compositions thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.
    Type: Grant
    Filed: March 30, 2000
    Date of Patent: May 1, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Flemming Elmelund Nielsen, John Bondo Hansen, Holger Claus Hansen, Tina Møller Tagmose, John Patrick Mogensen
  • Substituted guanidines and diaminonitroethenes, their preparation and use
    Patent number: 6147098
    Abstract: Guanidine and diaminonitroethene derivatives represented by the formula ##STR1## wherein X, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined in the description, compositions thereof and methods for preparing the compounds are described. The se compounds are useful in the treatment of diseases of the central nervous system, cardiovascular system, pulmonary system, gastrointestinal system and endocrinologic system.
    Type: Grant
    Filed: May 6, 1999
    Date of Patent: November 14, 2000
    Assignee: Novo Nordisk A/S
    Inventors: John Patrick Mogensen, John Bondo Hansen, Tina Moller Tagmose